Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.15 USD
Change Today -0.08 / -3.59%
Volume 1.4M
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

sequenom inc (SQNM) Snapshot

Open
$2.21
Previous Close
$2.23
Day High
$2.24
Day Low
$2.07
52 Week High
05/5/15 - $4.80
52 Week Low
08/24/15 - $1.82
Market Cap
254.7M
Average Volume 10 Days
1.2M
EPS TTM
$-0.10
Shares Outstanding
118.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEQUENOM INC (SQNM)

sequenom inc (SQNM) Related Businessweek News

View More BusinessWeek News

sequenom inc (SQNM) Details

Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women's health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene fetal Rhesus D (RhD) LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample. It also offers a microarray test that uses fetal samples obtained by amniocentesis or chorionic villus sampling under the NextView brand; additional carrier screening tests for Ashkenazi Jewish disorders, spinal muscular atrophy, and fragile X syndrome under the HerediT brand; and RetnaGene age-related macular degeneration (AMD) test to predict the risk of a patient with dry or early stage AMD progressing to wet or advanced choroidal neovascular disease within 2, 5, and 10 years. The company serves physicians and client laboratories. The company was founded in 1994 and is headquartered in San Diego, California.

448 Employees
Last Reported Date: 03/10/15
Founded in 1994

sequenom inc (SQNM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $433.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $343.9K
Chief Scientific & Strategy Officer, Executiv...
Total Annual Compensation: $407.6K
Senior Vice President of Corporate Governance...
Total Annual Compensation: $300.2K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $111.0K
Compensation as of Fiscal Year 2014.

sequenom inc (SQNM) Key Developments

Sequenom Enters Collaboration with UC San Diego Moores Cancer Center with Novel Liquid Biopsy Assay

Sequenom Inc. announced that it has entered into a clinical research collaboration with the University of California, San Diego Moores Cancer Center. Under this collaboration, Moores Cancer Center will explore the utility of Sequenom's new liquid biopsy assay to comprehensively profile circulating cell-free tumor DNA in blood to enable serial monitoring and assist with therapy selection in cancer patients. This technology has the potential to overcome the challenges and limitations associated with current methods such as imaging and invasive biopsies. Sequenom is currently developing a Research Use Only (RUO) assay with an initial focus on the detection and molecular profiling of late stage non-hematologic malignancies, where tissue biopsies are not available or too risky to obtain. The assay will cover a breadth of cancer types by analyzing over 100 cancer-related genes that are associated with a Food and Drug Administration (FDA)-approved drug treatment, included in professional society guidelines, linked to targeted therapies currently in clinical trials, or part of well-documented cancer pathways. The collaboration with UC San Diego Moores Cancer Center is the first of a series of collaborations with cancer centers worldwide that will utilize the assay as part of their clinical research programs. Sequenom, through its wholly owned subsidiary Sequenom Laboratories, intends to carry out further studies in order to bring to market a liquid biopsy assay for use in patient care in 2016.

Sequenom Inc. Presents at UBS Genomics 2.0 Summit, Aug-13-2015 11:45 AM

Sequenom Inc. Presents at UBS Genomics 2.0 Summit, Aug-13-2015 11:45 AM. Venue: The St. Regis Deer Valley, Park City, Utah, United States. Speakers: William J. Welch, Chief Executive Officer, President and Director.

Sequenom Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Sequenom Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $32,766,000 against $39,782,000 a year ago. Operating loss was $7,007,000 against 13,200,000 a year ago. Loss from continuing operations before income taxes was $8,965,000 against $15,292,000 a year ago. Loss from continuing operations was $9,013,000 against $8,364,000 a year ago. Net loss was $9,013,000 or $0.08 per share against net income of $4,453,000 or $0.04 per share a year ago. Net loss per common share basic and diluted was $0.08 against $0.07 per share a year ago. For the six months, the company reported total revenues of $70,572,000 against $76,843,000 a year ago. Operating income was $9,463,000 against operating loss of $27,647,000 a year ago. Earnings from continuing operations before income taxes were $5,396,000 against loss from continuing operations before income taxes of $31,837,000 a year ago. Earnings from continuing operations were $5,272,000 against loss from continuing operations of $25,033,000 a year ago. Net income was $5,272,000 or $0.04 per share against net loss of $11,221,000 or $0.10 per share a year ago. Net earnings per common share basic and diluted were $0.04 against net loss per common share basic and diluted of $0.22 per share a year ago. Net cash used in operating activities of continuing operations was $8,346,000 against $18,186,000 a year ago. Purchases of property, equipment and leasehold improvements were $1,626,000 against $551,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SQNM:US $2.15 USD -0.08

SQNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biotage AB kr18.00 SEK 0.00
Enzo Biochem Inc $2.92 USD +0.05
NanoString Technologies Inc $15.21 USD -0.05
Pacific Biosciences of California Inc $4.98 USD -0.09
Transgenomic Inc $1.25 USD +0.01
View Industry Companies
 

Industry Analysis

SQNM

Industry Average

Valuation SQNM Industry Range
Price/Earnings 16.5x
Price/Sales 1.8x
Price/Book NM Not Meaningful
Price/Cash Flow 15.1x
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEQUENOM INC, please visit www.sequenom.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.